Blencowe Resources: Aspiring to become one of the largest graphite producers in the world. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMycelx Di Regulatory News (MYX)

Share Price Information for Mycelx Di (MYX)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 54.50
Bid: 53.00
Ask: 56.00
Change: 0.00 (0.00%)
Spread: 3.00 (5.66%)
Open: 54.50
High: 54.50
Low: 54.50
Prev. Close: 54.50
MYX Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

New Project Awards and Operations Update

30 Aug 2022 07:00

RNS Number : 4589X
MyCelx Technologies Corporation
30 August 2022
 

30 August 2022

 

MYCELX Technologies Corporation

 

New Project Awards and Operations Update

 

MYCELX Technologies Corporation ("MYCELX" or the "Company"), the clean water and clean air technology company, is pleased to provide an update on recent operational momentum, including the award of new contracts in the Middle East.

 

MYCELX has secured a new purchase order from SABIC Agri-Nutrients, a SABIC affiliate, to provide clean water for optimal performance in their fertiliser production process. This installation is the fourth project with this customer and demonstrates MYCELX's status as vendor of choice for the toughest water treatment. The Company has also expanded its footprint in Saudi Arabia with the award of a short-term emergency response project with a leading independent petrochemical company. The Company expects that this initial project will develop into a longer-term partnership thereby helping to meet its goal of client diversification. In addition to this exciting work, MYCELX announces the renewal of two water treatment contracts with long-standing customers in the region and the establishment of a Master Framework Agreement with SABIC for Wastewater Treatment. This is a testament to the quality of the work and benefits MYCELX brings, the relationship the Company has with its customers and the excellence of its technology. These projects underpin the 2022 revenue forecast and the Company remains on track to meet current guidance.

 

MYCELX confirms the successful, ongoing trial of its unique REGEN product for use in Enhanced Oil Recovery with a major producer in the Middle East. The Company is also in advanced negotiations with another major producer for a REGEN retrofit of their existing equipment to benefit from MYCELX's superior removal efficiency, cost savings and the potential to increase flow rate by up to 30%. Beyond the Middle East, the Company is pleased to announce that a further REGEN system has now been installed and commissioned in Nigeria.

 

As part of MYCELX's strategy to expedite its access to the significant PFAS remediation market, the Company is pleased to confirm that it is currently in discussions with several global water treatment companies, an environmental engineering firm and companies focused on treatment for the residential market. Through these channels, the Company expects to run further PFAS trials in the USA. These will build upon the successful recent trial, through the Company's Australian distribution partner, at a landfill leachate installation where MYCELX PFAS technology was proven to remove contaminants down to non-detectable levels cost effectively. This broader capability in PFAS removal places MYCELX in a strong position as a cost-effective solution, as the enormity of the PFAS global problem is exposed and the need for complete removal gains public attention. We look forward to updating shareholders with further developments in the coming months.

 

Connie Mixon, CEO of MYCELX, said:

 

"I am pleased to provide an update in the Middle East, where our team continues to secure our position as the 'supplier of choice' for clean water solutions. In particular, REGEN is proving its performance and sustainability credentials through the successful ongoing trial in the sizeable enhanced oil recovery market. We look forward to providing more updates, including with regards to our critical PFAS remediation solution."

 

 

For further information please contact:

 

MYCELX Technologies Corporation

Connie Mixon, CEO

Kim Slayton, CFO

 

 

 

Tel: +1 888 306 6843

Canaccord Genuity, Nominated Adviser

Henry Fitzgerald-O'Connor

Gordon Hamilton

 

 

Tel: + 44 20 7523 8000

Celicourt

Mark Antelme

Jimmy Lea

 

Tel: +44 20 8434 2754

 

The relevant notifications set out below are provided in accordance with the requirements of Article 19 of the EU Market Abuse Regulation (No. 596/2014).

 

Notes to Editors

 

Through its revolutionary water technology, MYCELX brings its customers material benefits in terms of performance enhancement, cost savings and significantly improved environmental footprints. MYCELX supports leading international customers in the Oil & Gas industry, as well as the PFAS remediation market. MYCELX also provides advanced air filtration technology for manufacturing and industrial facilities, effectively removing oil particles and biologicals to maintain continuous and safe air quality levels.

 

For more information, visit www.MYCELX.com

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
STREANPNASFAEEA
Date   Source Headline
14th Oct 20217:00 amRNSMiddle East Contract Win
29th Sep 20217:00 amRNSHalf Year Results Statement
31st Aug 20217:00 amRNSNotice of Interim Results & Investor Presentation
11th Aug 20217:00 amRNSHolding(s) in Company
4th Aug 20217:00 amRNSContract Award and Contract Extension
7th Jul 20215:41 pmRNSResult of AGM
4th Jun 20218:00 amRNSMailing of Annual Financial Report and AM Notice
26th May 20217:00 amRNSFinal Results for the year ending 31 December 2020
19th May 20217:00 amRNSInvestor Presentation
14th May 20217:00 amRNSPFAS System Validation
13th Apr 20211:49 pmRNSGrant of Options
23rd Mar 20217:00 amRNSBoard Changes
17th Mar 20213:37 pmRNSHolding(s) in Company
17th Mar 20212:35 pmRNSHolding(s) in Company
15th Mar 20217:00 amRNSHolding(s) in Company
2nd Mar 20217:00 amRNSTrading Update
18th Feb 20217:00 amRNSSale of MYCELX property in Duluth, USA
17th Feb 20214:32 pmRNSHolding(s) in Company
5th Jan 20212:32 pmRNSHolding(s) in Company
4th Jan 20217:00 amRNSHolding(s) in Company
27th Oct 20202:55 pmRNSResult of Annual Meeting
2nd Oct 20202:56 pmRNSNotice of Annual Meeting
22nd Sep 20207:00 amRNSHalf Year Results Statement
4th Sep 20207:00 amRNSAppointment of Nominated Adviser and Sole Broker
7th Aug 202011:50 amRNSDirector/PDMR Shareholding
22nd Jun 20207:00 amRNSContract extension with SABIC
19th Jun 20207:00 amRNSAnnual Financial Report
27th May 20207:00 amRNSFinal Results for the year ending 31 December 2019
11th May 20207:00 amRNSNew Project Award
14th Apr 20207:00 amRNSTrading Update
9th Mar 20207:00 amRNSClosure of Restricted Stock Line
5th Mar 20207:00 amRNSTrading Update
13th Dec 201910:25 amRNSBlock listing Interim Review
4th Nov 20197:00 amRNSTrading Update
16th Sep 20197:00 amRNSHalf Year Results Statement
20th Aug 201912:42 pmRNSHolding(s) in Company
16th Aug 20193:02 pmRNSDirector Shareholding
29th Jul 20197:00 amRNSDirectorate Changes
26th Jul 20197:00 amRNSAppointment of Nominated Adviser & Broker
22nd Jul 20191:34 pmRNSHolding(s) in Company
10th Jul 201912:57 pmRNSResult of Annual Meeting
14th Jun 20197:00 amRNSTrading Update
11th Jun 20197:00 amRNSBlock listing Interim Review
6th Jun 20197:00 amRNSIssue of Equity
31st May 20191:57 pmRNSAnnual Financial Report
13th May 20197:00 amRNSFinal Results for the year ending 31 December 2018
28th Mar 20197:00 amRNSHolding(s) in Company
15th Mar 20197:00 amRNSHolding(s) in Company
15th Mar 20197:00 amRNSHolding(s) in Company
13th Mar 20197:00 amRNSIssue of Equity

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.